Sort
10,766 grants matching “checkpoint inhibitor”
IL-15 Characterization Through Experimental Immunology
$334,667Jianhua Yu · Beckman Research Institute/City Of Hope · R01 · FY2019 · CA
A novel therapeutic strategy to eradicate breast cancer through Hsp90 inhibition and reduced immune tolerance
$334,662Ahmed Chadli · Augusta University · R01 · FY2024 · CA
Dual function of HSP70 in cytoprotection of tumor cells and generation of permissive microenvironment
$334,662Hasan Korkaya · Wayne State University · R01 · FY2024 · CA
SPINK7 in allergic inflammation
$334,660Marc E. Rothenberg · Cincinnati Childrens Hosp Med Ctr · U19 · FY2018 · AI
How do cyclins drive the cell cycle?
$334,620Frederick R. Cross · Rockefeller University · R01 · FY2010 · GM
Selective Sensitization of Pancreatic Cancer to Therapy by Chk1 and PARP1 Inhibit
$334,466Meredith A Morgan · University Of Michigan At Ann Arbor · R01 · FY2014 · CA
Hec1 Network as Molecular Therapeutic Targets
$334,456Wen-Hwa Lee · University Of California-Irvine · R01 · FY2013 · CA
The replication checkpoint and genomic fidelity in skin
$334,455Paul Nghiem · University Of Washington · R01 · FY2013 · AR
Novel multipronged Immunovirotherapy Approach for GBM Treatment
$334,372Evanthia Galanis · Mayo Clinic Rochester · R01 · FY2025 · CA
Mechanisms of Selective Therapeutic Synergy of PARP-inhibition and CTLA4 Blockade Engaged by Interferon-gamma in the Ovarian Tumor Microenvironment
$334,312Sarah Foster Adams · University Of New Mexico Health Scis Ctr · R37 · FY2024 · CA
Modulating innate immune cells in the tumor microenvironment of pancreas cancer to enhance anti-tumor immunity
$334,305David C Linehan · University Of Rochester · R01 · FY2023 · CA
Targeting Stat3 to Improve Immunotherapy
$334,117Hua E Yu · Beckman Research Institute/City Of Hope · R01 · FY2011 · CA
Targeting Stat3 to Improve Immunotherapy
$334,117Hua E Yu · Beckman Research Institute/City Of Hope · R01 · FY2012 · CA
CHEK1 and WEE1 Inhibition as Therapeutic Strategies in AML
$334,116Raoul Tibes · Mayo Clinic Arizona · R01 · FY2014 · CA
The Role of BRCA1/BARD1 in Basal-like Breast Cancer
$333,954Richard J Baer · Columbia University Health Sciences · R01 · FY2010 · CA
Cellular responses to DNA replication stress
$333,951Marcus Smolka · Cornell University · R01 · FY2019 · GM
Cellular responses to DNA replication stress
$333,931Marcus Smolka · Cornell University · R01 · FY2018 · GM
Estrogen receptor beta is a targetable melanoma tumor suppressor
$333,894Craig J Burd · Ohio State University · R01 · FY2024 · CA
The Role of AKT in Prostate Cancer
$333,721William R Sellers · Beth Israel Deaconess Medical Center · P01 · FY2010 · CA
Cellular responses to DNA replication stress
$333,638Marcus Smolka · Cornell University · R01 · FY2020 · GM
Hematopoietic stem cells overcome treatment resistance to PD-1 blockade against brain tumors
$333,594Catherine T Flores · University Of Florida · R01 · FY2022 · NS
Hematopoietic stem cells overcome treatment resistance to PD-1 blockade against brain tumors
$333,594Catherine T Flores · University Of Florida · R01 · FY2020 · NS
Hematopoietic stem cells overcome treatment resistance to PD-1 blockade against brain tumors
$333,594Catherine T Flores · University Of Florida · R01 · FY2021 · NS
Hematopoietic stem cells overcome treatment resistance to PD-1 blockade against brain tumors
$333,594Catherine T Flores · University Of Florida · R01 · FY2023 · NS
Personalized targeting of anti-apoptosis pathways to overcome therapeutic resistance in melanoma
$333,518Michael Davies · Wistar Institute · U54 · FY2025 · CA